Literature DB >> 22925929

CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.

Sandra Hervas-Stubbs1, Uxua Mancheño, Jose-Ignacio Riezu-Boj, Ana Larraga, Maria C Ochoa, Diego Alignani, Carlos Alfaro, Aizea Morales-Kastresana, Iranzu Gonzalez, Esther Larrea, Hanspeter Pircher, Agnes Le Bon, Jose M Lopez-Picazo, Salvador Martín-Algarra, Jesus Prieto, Ignacio Melero.   

Abstract

Previous mouse and human studies have demonstrated that direct IFN-α/β signaling on naive CD8 T cells is critical to support their expansion and acquisition of effector functions. In this study, we show that human naive CD8 T cells primed in the presence of IFN-α possess a heightened ability to respond to homeostatic cytokines and to secondary Ag stimulation, but rather than differentiating to effector or memory CTLs, they preserve nature-like phenotypic features. These are qualities associated with greater efficacy in adoptive immunotherapy. In a mouse model of adoptive transfer, CD8 T cells primed in the presence of IFN-α are able to persist and to mediate a robust recall response even after a long period of naturally driven homeostatic maintenance. The long-lasting persistence of IFN-α-primed CD8 T cells is favored by their enhanced responsiveness to IL-15 and IL-7, as demonstrated in IL-15(-/-) and IL-7(-/-) recipient mice. In humans, exposure to IFN-α during in vitro priming of naive HLA-A2(+) CD8 T cells with autologous dendritic cells loaded with MART1(26-35) peptide renders CD8 T cells with an improved capacity to respond to homeostatic cytokines and to specifically lyse MART1-expressing melanoma cells. Furthermore, in a mouse model of melanoma, adoptive transfer of tumor-specific CD8 T cells primed ex vivo in the presence of IFN-α exhibits an improved ability to contain tumor progression. Therefore, exposure to IFN-α during priming of naive CD8 T cells imprints decisive information on the expanded cells that can be exploited to improve the efficacy of adoptive T cell therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22925929     DOI: 10.4049/jimmunol.1102495

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

2.  Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.

Authors:  Eugene M Cozza; Timothy K Cooper; Lynn R Budgeon; Neil D Christensen; Todd D Schell
Journal:  Cancer Immunol Immunother       Date:  2014-11-19       Impact factor: 6.968

3.  Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.

Authors:  Matthias Wölfl; Philip D Greenberg
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

Review 4.  Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms.

Authors:  Iñaki Etxeberria; Irene Olivera; Elixabet Bolaños; Asunta Cirella; Álvaro Teijeira; Pedro Berraondo; Ignacio Melero
Journal:  Cell Mol Immunol       Date:  2020-05-20       Impact factor: 11.530

5.  The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine.

Authors:  Kevin D Pavelko; Michael P Bell; Lavakumar Karyampudi; Michael J Hansen; Kathleen S Allen; Keith L Knutson; Larry R Pease
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

Review 6.  Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.

Authors:  Florian Wimmers; Gerty Schreibelt; Annette E Sköld; Carl G Figdor; I Jolanda M De Vries
Journal:  Front Immunol       Date:  2014-04-11       Impact factor: 7.561

Review 7.  Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.

Authors:  Giovanna Schiavoni; Fabrizio Mattei; Lucia Gabriele
Journal:  Front Immunol       Date:  2013-12-25       Impact factor: 7.561

Review 8.  Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.

Authors:  Michelle von Locquenghien; Catalina Rozalén; Toni Celià-Terrassa
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

9.  Dynamically expressed microRNA-15b modulates the activities of CD8+ T lymphocytes in mice with Lewis lung carcinoma.

Authors:  Guocheng Zhong; Xiaoming Cheng; Haixia Long; Luhang He; Wei Qi; Tong Xiang; Zhongquan Zhao; Bo Zhu
Journal:  J Transl Med       Date:  2013-03-21       Impact factor: 5.531

10.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.